LPCN Stock Overview
A clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Lipocine Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.28 |
| 52 Week High | US$11.79 |
| 52 Week Low | US$2.91 |
| Beta | 1.42 |
| 1 Month Change | 1.31% |
| 3 Month Change | -31.09% |
| 1 Year Change | -36.92% |
| 3 Year Change | -85.60% |
| 5 Year Change | -53.51% |
| Change since IPO | -99.04% |
Recent News & Updates
Recent updates
Lipocine announces plans to focus on treating CNS disorders, shares rise ~5%
Sep 26Does Lipocine (NASDAQ:LPCN) Have A Healthy Balance Sheet?
Feb 22
Is Lipocine (NASDAQ:LPCN) Using Debt Sensibly?
Sep 14Lipocine soars 9% on FDA greenlight for Phase 2 LPCN 1154 study in postpartum depression
Jun 14Lipocine competitor prevails in patent infringement lawsuit for Jatenzo
May 26When Will Lipocine Inc. (NASDAQ:LPCN) Turn A Profit?
May 11Lipocine EPS beats by $0.01
May 06Lipocine Inc. (NASDAQ:LPCN): Are Analysts Optimistic?
Jan 26Lipocine announces positive results from phase 2biopsy-confirmed NASH study
Jan 12FDA Ok's Lipocine's testosterone replacement therapy, tentatively
Dec 09Lipocine (NASDAQ:LPCN) Has Debt But No Earnings; Should You Worry?
Dec 04
Lipocine EPS misses by $0.01
Nov 10Lipocine: TLANDO Might Become A Potential TRT Option In Patients With COVID-19 Infection
Nov 06Shareholder Returns
| LPCN | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -7.3% | -2.0% | -1.8% |
| 1Y | -36.9% | -3.2% | 5.5% |
Return vs Industry: LPCN underperformed the US Pharmaceuticals industry which returned -3.6% over the past year.
Return vs Market: LPCN underperformed the US Market which returned 7.8% over the past year.
Price Volatility
| LPCN volatility | |
|---|---|
| LPCN Average Weekly Movement | 9.4% |
| Pharmaceuticals Industry Average Movement | 10.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: LPCN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: LPCN's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 16 | Mahesh Patel | www.lipocine.com |
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company’s pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor.
Lipocine Inc. Fundamentals Summary
| LPCN fundamental statistics | |
|---|---|
| Market cap | US$17.72m |
| Earnings (TTM) | US$8.35k |
| Revenue (TTM) | US$11.20m |
2,101x
P/E Ratio1.6x
P/S RatioIs LPCN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LPCN income statement (TTM) | |
|---|---|
| Revenue | US$11.20m |
| Cost of Revenue | US$0 |
| Gross Profit | US$11.20m |
| Other Expenses | US$11.19m |
| Earnings | US$8.35k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.0016 |
| Gross Margin | 100.00% |
| Net Profit Margin | 0.075% |
| Debt/Equity Ratio | 0% |
How did LPCN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/28 19:25 |
| End of Day Share Price | 2025/03/28 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Lipocine Inc. is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Scott Henry | Alliance Global Partners |
| John Newman | Canaccord Genuity |
| Corey Davis | Canaccord Genuity |